PRGN-3007
- Generic Name
- PRGN-3007
Precigen Announces Second Quarter and First Half 2024 Financial Results and Business Updates
Precigen, Inc. reported its financial results for the second quarter and first half of 2024, highlighting significant advancements in its PRGN-2012 gene therapy for recurrent respiratory papillomatosis (RRP), strategic portfolio reprioritization, and financial maneuvers to strengthen its cash position.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath